Introduction
Testosterone (TSTO) is a naturally occurring androgenic steroid based on the cyclopentanoperhydrophenanthrene skeleton of four rings. TSTO is produced mainly in ovaries, testes, and adrenal cortex, which could maintain muscle strength and
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Tang et al bone density, and enhance physical fitness at proper levels. 1 Meanwhile, it is a vital indicator of pathologic conditions. Since androgens including TSTO promote the growth of prostate cancer, androgen deprivation therapy (ADT) is used as the first-line clinical approach at present to treat advanced prostate cancer, and it is also applied as adjuvant or neoadjuvant treatment for high-risk prostate cancer. 2 However, the suppression of endogenous TSTO production has deleterious effects on quality of life, including hot flushes, reduced mood and cognition, and weakened sexual function. 3, 4 Therefore, it is meaningful to develop a method to specifically inhibit TSTO in prostate.
Molecularly imprinted polymers (MIPs), regarded as artificial antibodies, possess specific three-dimensional recognition cavities complementary to template in shape, size, and functionality. Their good physical and chemical stability, simple and economical production, durability, reusability, and high selectivity promote them to be widely applied in the fields of solid-phase extraction (SPE), 5, 6 chemical and biochemical sensors, 7, 8 heavy metals removal, 9 and drug delivery. 10 However, when traditional MIPs were used in the process of SPE, the centrifugation and filtration procedures were complex and time consuming. To solve this problem, Fe 3 O 4 magnetic nanospheres have been introduced into MIPs through surface imprinting technique, because of their attractive superior properties such as small size, high surface-to-volume ratio, and magnetic susceptibility.
11-13
The resultant MIPs not only have strong specific recognition ability, but also can be easily localized at a designated area in the presence of an external magnetic field. Thus, magnetic MIPs (MMIPs) could be an ideal nanomolecule to bind and remove TSTO from the prostate.
In the present study, a novel type of magnetic imprinted nanopolymers with good biocompatibility was developed adopting Fe 3 O 4 magnetic nanospheres, gelatin, and TSTO as carriers, functional monomer, and template molecule, respectively. The obtained MMIPs have spherical shape with a uniform and thin shell, and superparamagnetic property. Meanwhile, the resultant polymers exhibit fast kinetics, high adsorption capacity, excellent selectivity, and satisfactory reusability. The applicability of obtained MMIPs was investigated in the separation and determination of trace TSTO in LNCaP prostate cancer cell lysis solution. Moreover, it was determined whether the MMIPs suppress the function of TSTO in prostate cancer cells. We found that MMIPs could remove TSTO from prostate cancer cells and it may be a new option for the antiandrogen therapy in prostate cancer.
Materials and methods
Materials and apparatus
TSTO, dimethyl sulfoxide, methyltestosterone (MTSTO), testosterone propionate (TSTOP), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), progesterone (PROG), and dihydrotestosterone (DHT) were purchased from Sigma-Aldrich (St Louis, MO, USA). Type-B gelatin and 3-aminopropyltriethoxysilane (APTES) were obtained from Alfa Aesar Chemical Company (Lancashire, UK). Ferric chloride hexahydrate (FeCl 3 ⋅6H 2 O), glutaraldehyde (GA), anhydrous sodium acetate (NaOAc), acetic acid (HAc), ethylene glycol, hydrochloric acid (HCl), ethanol, methanol, and trihydroxymethylaminomethane (Tris) were provided by Xi'an Chemicals Ltd (Xi'an, People's Repub lic of China). Enzalutamide (MDV3100) was purchased from Selleck Chemicals (Houston, TX, USA). All the reagents were reconstituted and stored following the protocol. Pure water (18.0 MΩ cm
) was produced by a WaterPro water system (TY10AXLC1805-2; Axlwater Corporation, Shanghai, People's Republic of China) and used throughout the experiment. LNCaP human prostate cancer cells were obtained from the American Type Culture Collection (Manassas, VA, USA). C4-2 cell line was a gift from Dr Jer-Tsong Hsieh of University of Texas Southwestern Medical Center 14, 15 and the usage of this cell line was approved by the Institutional Review Board of the Medical School, Xi'an Jiaotong University. These two cell lines were cultured in Dulbecco's Modified Eagle's Medium/1640 supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillinstreptomycin at 37°C in humidified air containing 5% CO 2 . The morphology and structure of obtained materials were examined by a Tecnai G2 T2 S-TWIN transmission electron microscope. The infrared spectra were recorded on a Nicolet AVATAR-360 Fourier transform infrared spectrometer. The identification of the crystalline phase of resulted products was performed on a RigakuD/max/2500v/pc (Rigaku Corporation, Tokyo, Japan) X-ray diffractometer with a Cu Kα source. The 2θ angles probed were from 10° to 70° at a rate of 4° min . The magnetic properties were analyzed with a vibrating sample magnetometer (LDJ 9600-1; LDJ Electronics, Troy, MI, USA). A Shimadzu high-performance liquid chromatography (HPLC) system equipped with LC-10AT pump, SPD-M 10A detector, CTO-10AS column oven, and Shimadzu VP-ODS C18 column (5 μm, 150×4.6 mm) was used. The column temperature was 30°C. The mobile phase was methanol-water (70:30, v/v) delivered at a flow rate of 1.0 mL min −1 and injection volume 20 μL, and the column effluent was monitored at 254 nm. The absorbance of LNCaP Figure 1 . Two hundred milligrams of gelatin was dissolved in 30 mL of Tris-HCl buffer (10 mM, pH =7.0) with stirring at 50°C for 1 h to allow the entire dissolution of gelatin. TSTO (30 mg) was dissolved in 10 mL of ethanol and mixed with the above solution. The mixture was stirred at 50°C for 2 h to form the TSTO-gelatin complex. Then, the Fe 3 O 4 @CHO (300 mg) was suspended into the above mixing solution and allowed to proceed for 9 h at 50°C. The resultant nanomaterials were rinsed with highly purified water and ethanol until the supernatant was clear. Next, 10 mL of ethanol-HAc (94:6, v/v) was added as an eluent at intervals of half an hour to remove the template molecule TSTO with the help of shaking until no adsorption was detected in the eluent by HPLC at about 254 nm to assure that the template was completely washed. The nanomaterials were collected by an external magnetic field and repeatedly washed with highly purified water and ethanol, then dried under vacuum, and the Fe 3 O 4 @TSTO-MIPs were obtained. For comparison, ) of TSTO. The mixture was shaken at room temperature for 35 min. Then, the polymers were magnetically isolated and the residual TSTO in the supernatant was determined by HPLC.
In the selectivity experiments, the mixed standard solution (5 mL) of TSTO, DHT, MTSTO, TSTOP, and PROG at an initial concentration of 24.0 μg mL −1 was incubated with 10 mg of Fe 3 O 4 @TSTO-MIPs or Fe 3 O 4 @NIPs at room temperature for 35 min; then, the extraction and detection procedures were conducted as described earlier in the kinetics adsorption experiments.
The adsorption capacity (Q) of the TSTO or competitive compounds bound to the imprinted polymers was determined using Equation 1:
where C 0 and C e (mg mL
) represent the initial and the equilibrium solution concentration of the adsorbed compounds, respectively, V (mL) represents the volume of the solution, and W (mg) is the weight of the imprinted polymers.
Additionally, the imprinting factor (IF) and the selectivity coefficient (SC) are used to evaluate the selectivity properties of Fe 3 O 4 @TSTO-MIPs. The IF and SC are calculated from the following equations:
where Q MIP and Q NIP (mg g . The mixture was incubated at room temperature for 35 min. Then, the nanomaterials were collected by a magnet and the adsorption capacity for TSTO was detected by HPLC. The collected Fe 3 O 4 @TSTO-MIPs were washed with ethanol-HAc (94:6, v/v) for 6 h to ensure complete elution of residual TSTO and then washed with highly purified water for several times and dried under vacuum for reusing in successive adsorption of TSTO. 
Determination of TsTO in human prostate cancer lNcaP cell sample
real-time quantitative polymerase chain reaction assay
Cells were harvested with Trizol reagent (Thermo Fisher Scientific, Waltham, MA, USA) to extract total RNA and the procedures were described previously. 17 The primer sequences were as follows: PSA (F: 5′-GTGTGTGGACCTCCAT-GTTATT-3′, R: 5′-CCACTCACCTTTCCCCTCAAG-3′); FKBP5 (F:
Immunofluorescence assay prior to being fixed in 4% paraformaldehyde for 30 min. Cells were subsequently washed with PBS again, treated with permeabilization solution (1% Triton X-100 in PBS), washed with PBS three times, and blocked with 1% bovine serum albumin (Sigma-Aldrich) in PBS for 1 h. Samples were subsequently incubated with anti-androgen receptor (AR) primary antibody (N-20; Santa Cruz Biotechnology Inc., Dallas, TX, USA) in antibody dilution buffer (1% bovine serum albumin in 1× PBS) overnight at 4°C. Samples were washed with PBS three times and incubated with secondary antibody fluorescein isothiocyanate-conjugated affinipure goat antirabbit IgG (#ZF-0315; dilution, 1:200; Beijing Zhongshan Golden Bridge Biotechnology, Co., Ltd.) for 60 min at room temperature, followed by DAPI staining (1:5,000) for 5 min in the dark. Samples were examined using laser scanning confocal microscopy (Nikon A1R/A1).
MTT assay
Cell viability and growth rate were measured by the MTT assay, as described previously. 18 
Flow cytometric analysis
Flow cytometric analysis was performed to evaluate the effects of MMIPs on cell cycle distribution, as we described previously. 19 Flow cytometry was performed using an FACS Calibur (Becton Dickinson, San Jose, CA, USA) system with CELLQuest software (version 3.3; Becton Dickinson). All experiments were carried out in triplicate to assess the consistency of response.
statistical analysis
All the statistical analyses were performed with GraphPad Prism software (version 5.0), and Student's t-test was used for comparison of two groups. For each result, at least three independent experiments were performed to obtain statistical significance. P,0.05 was considered as statistically significant.
Results
Preparation of Fe 3 O 4 @TsTO-MIPs
The method for synthesis of Fe 3 O 4 @TSTO-MIPs through a multistep procedure is shown in Figure 1 . Firstly, the Fe 3 O 4 nanospheres were prepared by a modified solvothermal reaction. 16 Secondly, the Fe 3 O 4 nanospheres were functionalized with APTES by a sol-gel process to obtain aminemodified Fe 3 Gelatin is a nontoxic, nonimmunogenic, and biodegradable biomacromolecule, which contains abundant active groups including NH 2 , -COOH, and −OH and possesses native hydrophilic and hydrophobic segments. 21, 22 These distinctive features make gelatin an ideal functional monomer agent to develop MIPs with good biocompatibility.
To obtain the best recognition performance of Fe 3 O 4 @ TSTO-MIPs, the amount of gelatin ranging from 50 to 300 mg was evaluated. As shown in Figure 2 , the amount of functional monomer affected the adsorption capacity greatly due to change in the number of recognition sites in the network of polymers. It was observed that Q and IF increased with an increase in the amount of gelatin from 50 to 200 mg, suggesting augmentation in the number of recognition cavities in the Fe 3 O 4 @TSTO-MIPs. However, the downtrends of Q and IF emerged with further increase in the mass of gelatin from 200 to 300 mg, which may be because excessive amount of functional monomer might lead to homogeneous selfcondensation and decrease the number of recognition cavities. Herein, 200 mg of gelatin was adopted in our work. Figure 5B . It could be seen that the adsorption process was time dependent. The adsorption capacity increased rapidly in the first 25 min, and then the adsorption rate exhibited a slower increase to reach the adsorption equilibrium after 35 min. It is worth noting that the adsorption capacity of Fe 3 O 4 @TSTO-MIPs was much higher than that of Fe 3 O 4 @NIPs, suggesting the excellent imprinting effect of the imprinted polymers. These results manifested that the formed thin imprinted shell dramatically improved the mass transfer for easy diffusion of TSTO into the binding cavities.
characterization of obtained nanomaterials
selectivity of Fe 3 O 4 @TsTO-MIPs
To investigate the selectivity of Fe 3 O 4 @TSTO-MIPs, four structural analogs (DHT, PROG, MTSTO, and TSTOP) were 
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Tang et al selected as competitive compounds. As shown in Table 1 , the Q of Fe 3 O 4 @TSTO-MIPs toward TSTO was higher than that of the other four analogs, suggesting that the imprinted nanomaterials had higher affinity for the template molecule than its analogs. Moreover, the recognition capacity of Fe 3 O 4 @TSTO-MIPs for the four analogs showed an appreciable difference with the order DHT.MTSTO.PROG.TSTOP. This may be because of their different molecular structures ( Figure S1 ). They had a similar skeleton with the template molecule TSTO, except that DHT and MTSTO had an additional hydrogen atom and an extra methyl group, while the hydroxyl group of TSTO was replaced by the ketone group of PROG or the propionic group of TSTOP. The absence of hydroxyl group on PROG and TSTOP may account for their weaker ability to form hydrogen bond with gelatin, compared with DHT and MTSTO. Meanwhile, MTSTO and TSTOP possessed much more steric hindrance effect compared with TSTO and PROG, when recognized by 
reusability of Fe 3 O 4 @TsTO-MIPs
The adsorption-desorption cycle was repeated six times by using the same Fe 3 O 4 @TSTO-MIPs to evaluate their stability, and the results are shown in Figure S2 . The adsorption capacity of Fe 3 O 4 @TSTO-MIPs maintained at an almost steady value of 93.7% after six adsorption-regeneration cycles. The 6.3% decrease may be because some recognition cavities in the imprinted shells were clogged after regeneration or were destroyed after washing. The Q of Fe 3 O 4 @NIPs remained almost unchanged due to the nonspecific effect, thus the influence of washing procedures could be negligible. These results confirmed that Fe 3 O 4 @TSTO-MIPs are stable and have great potential for practical application.
Method validation and real sample analysis
The analytical performance of the methods, including linear range, limit of detection (LOD), precision, and accuracy, was investigated. A high correlation coefficient (0.9994) was obtained for TSTO in the linear concentration range of 1.0-100 ng mL −1 . LOD (signal to noise ratio=3) reflecting the sensitivity of the analytical method was found to be 0.05 ng mL −1 . The precision of the method was assessed by determining the relative standard deviations (RSDs) of intraday and interday at three different spiked levels. The results show that the RSD of intraday precision was 2.1%-3.2%, while that of interday precision was 3.7%-6.8%. To investigate the accuracy of the developed method, human prostate cancer LNCaP cell sample spiked with three levels (1.0, 5.0, and 50.0 ng mL −1 ) of TSTO was analyzed. The recovery of TSTO ranged from 99.1% to 102.9% with RSD ,6.8%, suggesting that the accuracy of Fe 3 O 4 @TSTO-MIPs coupled with HPLC was satisfactory for the analysis of trace TSTO in the human prostate cancer LNCaP cell samples.
Different strategies for determination of TSTO are listed briefly in Table 2 . As can be seen, the present method had a relatively low LOD among the other reported approaches. 9, 10, 23, 24 Meanwhile, Fe 3 O 4 @TSTO-MIPs used as SPE extractant possessed satisfactory selectivity and excellent stability, compared with the standard SPE C18 sorbents 24 and immunoaffinity capillary column, 10 respectively. In conclusion, the present method is reliable, effective, and sensitive.
The proposed method was applied for specific enrichment and determination of TSTO in the human prostate cancer LNCaP cell sample. The typical chromatograms of LNCaP cell sample spiked with TSTO at a concentration of 5.0 ng mL −1 and the elution of adsorbed Fe 3 O 4 @TSTO-MIPs are shown in Figure 6 . Figure 6 shows that the peak of TSTO cannot be found from the chromatogram of the spiked LNCaP cell sample and there are some other peaks reflecting the LNCaP cell sample. After the enrichment of spiked LNCaP cell sample with Fe 3 O 4 @TSTO-MIPs and elution by ethanol-HAc (94:6, v/v) solution, the peak of TSTO was found distinctly at 5.40 min ( Figure 6 ) and other interference peaks almost disappeared. The results verified that TSTO in spiked LNCaP cell sample could be selectively enriched 
This study
Abbreviations: hPlc-DaD, high-performance liquid chromatography system equipped with a diode array detector; lc, liquid chromatography; lIF, laser-induced fluorescence detection; LOD, limit of detection; MIPs, molecularly imprinted polymers; MISPE, molecularly imprinted solid-phase extraction; MS, mass spectrometry; SPE, solid-phase extraction; TsTO, testosterone; UV, ultraviolet. 
respectively, and then the cells were observed under a microscope. As shown in Figure 7 , we found that MIP magnetic nanospheres could freely enter the cells and the state of cells was not changed within 24 h.
MMIPs inhibit the function of TsTO in prostate cancer cells
Since MMIPs can freely enter prostate cancer cells and TSTO should be absorbed by MMIPs, we further determined whether MMIPs could inhibit the function of TSTO in prostate cancer cells. AR is a type I nuclear receptor that can be activated by androgens such as TSTO and DHT, and the binding of androgen and AR triggers a cascade of events involving conformational changes and nuclear translocation, binding of AR dimer to the promoter and enhancer regions of target genes, and gene transcription. 25 Therefore, firstly, we found whether the treatment of MMIPs (160 μg mL −1 , 24 h) inhibited the nuclear translocation of AR in LNCaP and C4-2 prostate cancer cells by immunofluorescence assays, and castration medium without androgen and MDV3100 (20 nM, 24 h), which is a direct inhibitor of AR, were used as positive controls. We found that the nuclear translocation of AR in both LNCaP and C4-2 cells was dramatically inhibited by the treatment of MMIPs in cell culture medium (Figure 8 ).
To detect whether the function of TSTO-AR was inhibited by MMIPs in prostate cancer cells, we treated LNCaP cells of MMIPs, and 320 μg mL −1 of MMIPs, respectively, and determined the expression of PSA, FKBP5, and TMPRSS2, which are the target genes of TSTO-AR, through real-time quantitative polymerase chain reaction assays. Moreover, to confirm whether MMIPs absorb TSTO specifically, we also treated those cells with 10 ng mL −1 of DHT in six other groups. We found that the expression levels of TSTO-AR target genes decreased when cells were treated with CSS, MDV3100, and MMIPs; on the other hand, DHT could rescue the suppression of AR target genes by MMIP treatment (Figure 9 ), suggesting that MMIPs inhibited the function of TSTO-AR, but not DHT-AR in prostate cancer cells, and the inhibition was through the binding of MMIPs with TSTO, but not DHT. Taken together, our results indicate that MMIPs can inhibit the activation of TSTO-AR pathway through binding with TSTO and sequestering AR in cell cytoplasm in prostate cancer cells.
MMIPs inhibited cell proliferation and induced cell cycle arrest in lNcaP, but not c4-2 prostate cancer cells
To further determine whether MMIPs suppress the effect of TSTO on prostate cancer cells, we treated androgen-dependent LNCaP prostate cancer cells and androgen-independent C4-2 cells, whose growth is promoted by oncogenic pathways other than androgen-triggering AR activity, with different concentrations of MMIPs and measured cell growth by MTT assays. As shown in Figure 10A , we found that MMIPs inhibited cell growth of LNCaP cells in a dose-dependent and time-dependent manner, indicating that MMIPs inhibited the effect of TSTO on prostate cancer cell growth. Furthermore, we detected whether MMIPs inhibited cell growth through the suppression of cell cycle progression by cell flow cytometry analysis, and found that MMIPs induced G1 cell cycle arrest in LNCaP cells ( Figure 11A ). On the other hand, MMIP treatment did not affect the cell growth and cell cycle progression of C4-2 cells (Figures 10B and 11B) . Our results indicate that MMIPs can block the function of TSTO in cell growth and cell cycle progression of early-stage prostate cancer cells.
Discussion
Prostate cancer is one of the most common malignancies in males in the USA. 26 In the present study, to remove androgen from prostate cancer cells, novel MMIPs, Fe 3 O 4 @TSTO-MIPs, using TSTO as the template molecule, were synthesized and characterized. They possessed high crystallinity and satisfactory superparamagnetic properties, and the obtained polymers exhibited fast kinetics, high adsorption capacity, and excellent selectivity for the template molecule TSTO. Subsequently, we found that the imprinted nanomaterials could successfully recover TSTO in LNCaP prostate cancer cell samples and freely enter LNCaP cells. Furthermore, MMIPs could suppress the translocation of AR into cell nucleus, inhibit the function of AR, and induce obvious cell cycle arrest in LNCaP cells. Taken together, our results indicate that the new synthesized Fe 3 O 4 @TSTO-MIP is an efficient carrier to remove or recover TSTO from the cell lysates and living cells.
Application of ADT in prostate cancer is increasing in recent years. 2 ADT can be applied by orchiectomy (castration) in surgery or by taking a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone Notes: cells were treated with normal cell culture medium (control), medium without androgen (no androgen), MDV3100, and different concentration of MMIPs for 24 h, and then 10 ng ml −1 DhT was added and made to react for 12 h. Abbreviations: ar, androgen receptor; DhT, dihydrotestosterone; MMIPs, magnetic molecularly imprinted polymers.
antagonist orally. All these methods block TSTO in the whole body, leading to several side effects, such as adverse bone and cardiometabolic effects, in prostate cancer patients. 3, 4 In this study, we found that MIPs can recognize molecular targets with very high selectivity due to their specific binding sites with complementary size, shape, and functional groups to the template molecules. [27] [28] [29] Moreover, surface imprinting has adopted various supports such as Fe 3 O 4 magnetic nanospheres during the past years, 16, 30, 31 which can efficiently separate complicated matrices with an external magnet. To date, TSTO-imprinted polymers that were previously reported have been mostly prepared in organic solvents, [11] [12] [13] which could lead to poor recognition ability in biologic samples. The Fe 3 O 4 @TSTO-MIPs we synthesized can not only recognize TSTO specifically with high affinity in human cells, which suggests that it can be used to determine the concentration of androgens in body liquid, different cells and organs, but also inhibit the function of TSTO through binding to it and sequestrating it in the cell cytoplasm. In addition, since it is a kind of magnetic nanosphere, it could be guided to a designated area in the body, such as prostate. Thus, its particular advantage in the ADT is that the inhibition on TSTO could be limited in the prostate and the function of TSTO in other organs will not be affected. The application of Fe 3 O 4 @ TSTO-MIPs in the ADT of early-stage prostate cancer may block the function of TSTO and inhibit cell proliferation efficiently while causing lesser side effects.
Conclusion
A simple and mild approach was developed to prepare a novel kind of magnetic imprinted nanospheres with good biocompatibility for isolation and detection of TSTO in biologic samples. The obtained imprinted nanomaterials exhibited fast kinetics, high adsorption capacity, and satisfactory selectiv- 
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Tang et al the newly synthesized Fe 3 O 4 @TSTO-MIPs is an efficient carrier to remove or recover TSTO from the cell lysates and living cells, and it could be a new option for antiandrogen therapy in prostate cancer.
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